Paul Wheatley‐Price
University of Ottawa · 257 works · 4,913 citations · h-index 36
Top works
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
- Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
- The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
- Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis
- Prevention and Management of Bone Metastases in Lung Cancer: A Review
- The incidence and clinical impact of bone metastases in non-small cell lung cancer
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
- Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma
- Incidence and consequences of bone metastases in lung cancer patients
- Prospective Validation of Risk Prediction Indexes for Acute and Delayed Chemotherapy-Induced Nausea and Vomiting
- Prospective Validation of a Prediction Tool for Identifying Patients at High Risk for Chemotherapy-Induced Nausea and Vomiting
- Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes
- Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
- Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review
- Risk Model–Guided Antiemetic Prophylaxis vs Physician’s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer
- The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
- Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real-World Population of Advanced Non-Small-Cell Lung Cancer Patients?
- Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma